# Xiamen Amoytop Biotech Co., Ltd. clinical trials: 33 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 33 trials with Xiamen Amoytop Biotech Co., Ltd. as lead sponsor, 12 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Xiamen Amoytop Biotech Co., Ltd.: 33 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/xiamen-amoytop-biotech-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 33
- Recruiting or not yet: 12
- Read on: November 19, 2026

## Trials

The 25 newest of 33, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946757 | Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Not yet recruiting | Chronic Hepaititis B | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946757) |
| November 10, 2026 | NCT07929805 | ACT201 Injection in Participants With Chronic Hepatitis B (CHB) on Nucleos(t)Ide Analog Therapy - Phase Ib | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Not yet recruiting | Chronic Hepaititis B | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929805) |
| October 26, 2026 | NCT07894341 | A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed... | Xiamen Amoytop Biotech Co., Ltd. | Not applicable | Recruiting | Idiopathic Short Stature | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894341) |
| August 3, 2026 | NCT07741461 | ACT201 Injection in Healthy Participants and Participants With Chronic Hepatitis B (CHB) | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Recruiting | Chronic Hepaititis B | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741461) |
| May 29, 2026 | NCT07614152 | The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature | Xiamen Amoytop Biotech Co., Ltd. | Phase 3 | Recruiting | Turner Syndrome | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614152) |
| May 15, 2026 | NCT07589400 | Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated... | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Not yet recruiting | Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589400) |
| April 27, 2026 | NCT07551804 | Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency | Xiamen Amoytop Biotech Co., Ltd. | Phase 2 | Recruiting | Adult Growth Hormone Deficiency | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551804) |
| March 10, 2026 | NCT07462455 | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver... | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Not yet recruiting | Metabolic Dysfunction-associated Steatohepatitis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462455) |
| February 13, 2026 | NCT07408908 | Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants.. | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07408908) |
| December 30, 2025 | NCT07309562 | The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age | Xiamen Amoytop Biotech Co., Ltd. | Phase 3 | Recruiting | Small for Gestational Age | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07309562) |
| April 15, 2025 | NCT06927310 | The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature | Xiamen Amoytop Biotech Co., Ltd. | Phase 3 | Recruiting | Idiopathic Short Stature | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06927310) |
| April 11, 2025 | NCT06924385 | Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Completed | Preeclampsia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06924385) |
| March 25, 2025 | NCT06893796 | Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Completed | Preeclampsia | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06893796) |
| December 4, 2024 | NCT06716905 | Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Completed | Non-alcoholic Steatohepatitis | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06716905) |
| November 27, 2024 | NCT06707922 | A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B | Xiamen Amoytop Biotech Co., Ltd. | Not applicable | Enrolling by invitation | Chronic Hepatitis B | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06707922) |
| August 14, 2024 | NCT06552429 | Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET | Xiamen Amoytop Biotech Co., Ltd. | Phase 2 | Recruiting | Essential Thrombocythemia | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06552429) |
| May 3, 2023 | NCT05838885 | A Trial of YPEG-rhGH in Children With Short Stature | Xiamen Amoytop Biotech Co., Ltd. | Phase 2 | Completed | Idiopathic Short Stature, Small for Gestational Age, Turner Syndrome | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05838885) |
| May 13, 2021 | NCT04885647 | A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease | Xiamen Amoytop Biotech Co., Ltd. | Phase 2 | Completed | Renal Anemia of Chronic Kidney Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04885647) |
| April 15, 2021 | NCT04846491 | A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B | Xiamen Amoytop Biotech Co., Ltd. | Phase 3 | Completed | Chronic Hepatitis B | 475 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04846491) |
| August 14, 2020 | NCT04513171 | Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children | Xiamen Amoytop Biotech Co., Ltd. | Phase 2/3 | Completed | Growth Hormone Deficiency | 434 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04513171) |
| July 10, 2020 | NCT04466137 | Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy | Xiamen Amoytop Biotech Co., Ltd. | Phase 3 | Completed | Non-Myeloid Malignancy | 398 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04466137) |
| June 8, 2017 | NCT03181113 | Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy | Xiamen Amoytop Biotech Co., Ltd. | Observational | Completed | Hepatitis B | 473 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03181113) |
| January 6, 2015 | NCT02332473 | A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B | Xiamen Amoytop Biotech Co., Ltd. | Phase 2 | Completed | Chronic Hepatitis B | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02332473) |
| December 9, 2013 | NCT02005458 | Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy | Xiamen Amoytop Biotech Co., Ltd. | Phase 2 | Completed | Non Small Cell Lung Cancer, Breast Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02005458) |
| February 27, 2013 | NCT01800305 | PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual | Xiamen Amoytop Biotech Co., Ltd. | Phase 1 | Completed | Healthy | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01800305) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 2 | 8 |
| Phase 2/3 | 1 |
| Phase 3 | 7 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Recruiting | 7 |
| Not yet recruiting | 5 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis B, Chronic | 6 |
| Turner Syndrome | 2 |
| Hepatitis C, Chronic | 2 |
| Febrile Neutropenia | 2 |
| Neutropenia | 2 |
| Hepatitis B | 2 |
| Pre-Eclampsia | 2 |
| Dwarfism, Pituitary | 2 |
| Recurrence | 1 |
| Anemia | 1 |
| Renal Insufficiency, Chronic | 1 |
| Dwarfism | 1 |
| Thrombocythemia, Essential | 1 |
| Liver Diseases | 1 |
| Hepatitis, Chronic | 1 |
| Hepatitis, Viral, Human | 1 |
| Hepadnaviridae Infections | 1 |
| Virus Diseases | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Lupus Erythematosus, Cutaneous | 1 |
| Mycoses | 1 |
| Non-alcoholic Fatty Liver Disease | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Breast Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Truck parts suppliers in the United States](https://specstream.ai/data/businesses/truck-parts-suppliers/united-states)
- [Bathroom remodelers in the United States](https://specstream.ai/data/businesses/bathroom-remodelers/united-states)
- [Electric utilities in the United States](https://specstream.ai/data/businesses/electric-utilities/united-states)
- [Interior design firms in the United States](https://specstream.ai/data/businesses/interior-design-firms/united-states)
- [Persian restaurants in the United States](https://specstream.ai/data/businesses/persian-restaurants/united-states)
- [Test preparation centers in the United States](https://specstream.ai/data/businesses/test-preparation-centers/united-states)
